Preoperative radiochemiotherapy in T3 operable low rectal cancer: a gold standard? by Fucini, Claudio et al.
Preoperative Radiochemotherapy in T3 Operable Low Rectal
Cancers: A Gold Standard?
Claudio Fucini • Filippo Pucciani • Claudio Elbetti •
Riccardo Gattai • Antonio Russo
Published online: 6 March 2010
 Socie´te´ Internationale de Chirurgie 2010
Abstract
Background Preoperative chemoradiation followed by
total mesorectal excision (TME) has become a standard
treatment of preoperatively staged T3 low rectal cancers in
many institutions; however, a direct comparison of gen-
eralized preoperative versus selective adjuvant chemoradi-
ation has never been assessed in a clinical practice setting.
Patients Over a 4-year period, 80 patients with T3 primary
low adenocarcinoma of the rectum, judged operable at
preoperative staging, were offered preoperative chemoradi-
ation. Forty-seven patients (Group I) accepted the neoadju-
vant treatment and 33 (Group II) preferred immediate
surgery and postoperative chemoradiation if indicated.
Results Major postoperative complications occurred in
21% of Group I versus in 11% of Group II (p = 0.3)
patients. After a mean follow-up of 92 months, the local
recurrence rate was 4 and 9% (p = 0.4), metastasis rate
was 30 and 24% (p = 0.5), 5-year survival probability was
0.79 (95% CI = 0.49–0.92) and 0.82 (95% CI = 0.70–
1.00) (log-rank test, p = 0.6) for Group I and Group II,
respectively.
Conclusions In T3 operable low rectal cancers, selective
postoperative radiochemotherapy yielded similar long-term
results regarding recurrence rate and survival as extended
preoperative chemoradiation.
Introduction
Complete removal of the rectum using total mesorectal
excision (TME) is the treatment usually adopted for resect-
able rectal cancers less than 10 cm from the anal margin [1,
2]. Local recurrence rates of less than 10% and improved
survival have been reported for locally invasive (T3) tumors
following this procedure [3, 4]. To further reduce local
recurrence and increase long-term survival, pre- or postop-
erative chemoradiation (RT ? CHT) had been adopted as
neoadjuvant or adjuvant treatment in locally advanced
(AJCC/UICC stage II-T3/4N0 and stage III-N1/2) low rectal
cancer [5–9]. A recent trial reported that preoperative che-
moradiation combined with TME surgery has less morbidity
and better control of the local recurrence rate than postop-
erative chemoradiation and without increased adverse
effects [10]. Consequently, the neoadjuvant approach is
increasingly adopted in many institutions despite the toxicity
of chemoradiation, and in patients subjected to conservative
procedures, the impairment of postoperative anorectal
function remains matter of concern [11, 12].
There has been some criticism regarding the adoption of
preoperative chemoradiation in preoperatively staged II
cancers expressed by some authors [13, 14] since 18% of
patients examined with endorectal ultrasound (ERUS) and
magnetic resonance imaging (MRI) [10] are overstaged
and therefore overtreated, and, in addition, T3N0 cancers
with no involvement of mesorectal circumferential margin
do not need neo- or adjuvant treatment [13, 14]. However,
given that more than 22% of preoperatively staged T3
patients seem to have undetected mesorectal lymph node
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involvement, other authors [15] contend that the extensive
adoption of preoperative chemoradiation is appropriate as
long as there is a reliable method of selecting patients who
could benefit from this complementary treatment. In fact,
clear-cut evidence of the advantages of preoperative che-
moradiation in T3 operable rectal cancer either in stage II
or III is still missing. A recent trial (MRC CR07 and NCIC-
CTG C016, [16]) has evaluated the results of preoperative
short-course radiotherapy (25 Gy/5F) versus postoperative
chemoradiation limited to patients with involvement of
circumferential resection margin. A reduction of local
recurrence and an improvement in disease-free survival in
the neoadjuvant arm of the study has been reported.
Unfortunately, a similar trial examining preoperative che-
moradiation versus selective adjuvant chemoradiation in
subjects with T3 operable cancers is still absent.
In this article we examined the long-term results of a
prospective observational study on a selected group of
patients with T3 resectable low rectal cancer who were
subjected, in a limited period of time, to preoperative
chemoradiation or underwent selectively a more conven-
tional treatment: immediate surgery followed by chemo-
radiation [17] when indicated.
Patients and methods
In a 4-year period (1997–2000) 80 patients with T3
resectable low rectal cancer measured by rigid rectoscopy at
10 cm or less from the anal margin were seen by the mul-
tidisciplinary oncologic team of our department. The
median age was 63 years (range = 39–80 years). The
tumors were deemed T3 cancers, resectable with curative
intent with total mesorectal excision (TME), by means of
clinical examination, abdominopelvic CT scan, endorectal
sonography, chest X-ray, and at times by MRI with endo-
rectal coil. No attempt was made to evaluate lymph node
status. After explaining extensively the goals and the risk of
neoadjuvant versus selective adjuvant treatment, preopera-
tive chemoradiation was offered to all patients. Forty-seven
patients [Group I, 28 men, mean age = 63 ± 9 (range =
45–77) years] accepted the neoadjuvant treatment, while 33
[Group II, 19 men, mean age = 64 (range = 39–80) years]
preferred immediate surgery. Preoperative radiation therapy
(RT) fields included the primary tumor, the adjacent lymph
node drainage area in the pelvis, and the regional nodes
along the superior hemorrhoidal vessels. The tumor dose
was 45 Gy delivered in 25 daily doses of 1.8 Gy each.
Chemotherapy consisted of fluorouracil (5-FU 375 mg/m2
bolus daily for 5 days) and leucovorin (LV) (10 mg/m2
daily for 5 days). The treatment was administered concur-
rently during the first 5 days and days 29–33 of radiation
therapy.
Postoperative chemoradiation started 4–6 weeks after
surgery with chemotherapy given for two cycles every
28 days at the same dosage reported above. After the two
cycles of 5-FU plus LV, radiotherapy was initiated at a
daily dose of 2 Gy over a period of 5 weeks (54 Gy).
All patients with positive nodes in both groups were
scheduled to receive four extra cycles of postoperative
chemotherapy.
The patients who received the neoadjuvant treatment had
a new complete diagnostic workup before surgery was
performed 6–9 weeks after completion of therapy. Forty-
eight patients had an anterior resection with a coloanal
anastomosis. Thirty-two patients had an abdominoperineal
excision. All patients were enrolled in an institutional fol-
low-up based on clinical examination, CEA monitoring,
colonoscopy, and CAT scan of the abdomen and thorax to
follow the progression of the disease. Median follow-up
was 92 months (range = 84–132 months). Perioperative
results, local recurrence rate, metastatic relapse, and cancer-
specific and overall survival were examined for each group.
Statistical analysis
The distribution of individual characteristics of two treat-
ment groups was evaluated by simple descriptive statistics
and variable frequency and the distributions were com-
pared using the Fisher exact test. The Wilcoxon rank-sum
tests for unpaired data were performed for statistical
evaluation of the significant difference between the two
groups for continuous variables.
The index date for calculation of survival was defined as
the date of primary treatment (RT ? CHT or surgery). The
observed survival was estimated using the Kaplan–Meier
product limit method, and cumulative survival probability
was calculated at 5 years, stratified according to treatment
group. Differences were tested using the log-rank test. To
assess the relative excess risk of death or recurrence
according to treatment group and to control for con-
founding factors (age as a continuous variable, gender),
proportional hazard models were fitted by computing the
hazard ratio (HR) and the corresponding 95% confidence
intervals (95% CI). The proportional assumption was
examined with log–log survival plots or by adding time-
dependent interaction terms into the model.
Results
Perioperative comparisons
Groups I and II were comparable with regard to gender,
age, and the distribution of type of operation, i.e.,
abdominoperineal excision versus sphincter-sparing
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(Table 1). All Group I patients completed the preoperative
treatment despite the appearance of grade II and grade III
toxicity (NCI scale) (skin, small bowel, hematological
changes) in 12 of them. Forty patients were noted to have a
clinical reduction of the tumor mass. Twenty Group II
patients had surgery alone (13 men), 13 had postoperative
chemoradiation because of lymph node involvement in 11
(N?) and/or infiltration or close proximity of the tumor
edge to the lateral or distal margins of the specimen in 2.
In seven patients with anastomoses at the dentate line,
the upper part of the internal sphincter was excised with the
rectum. At surgery, all patients were considered locally
cured. A temporary protective colostomy or ileostomy was
performed at the time of surgery in all patients who
underwent sphincter-sparing procedures and was closed 8-
20 weeks later. In Group II patients the stoma was closed
after the completion of adjuvant chemoradiation.
Postoperative pathologic features (TNM-UICC) of
patients who had preoperative chemoradiation or primary
surgery are given in Table 2. A complete pathologic
remission of the tumor was observed in 12 (25%) of 47 and
a partial response was observed in 8 patients of Group I, for
a tumor downstaging rate of 42% (Table 2). All cancers of
Group II were correctly staged as T3 at preoperative
workup.
Microscopically clear surgical margins (radial, proxi-
mal, and distal) were obtained in 43 (91%) patients in
Group I and in 30 (90%) of those who had primary surgery.
All patients with invasion of the surgical margins in Group
I had concomitant invasion of lymph nodes. Of the 33
patients who had primary surgery, 11 had pathologic
positive lymph nodes, one with concomitant microscopic
tumor invasion of the lateral section margins. All these
patients received postoperative chemoradiation as well as
two others with invasion limited to the lateral margins.
Postoperative morbidity
One patient (2%) of Group I died postoperatively from a
pulmonary embolism. Postoperative morbidity was 43%
for Group I and 44% for Group II. Major complications,
namely, complications requiring further surgery, intensive
medical support, and prolonged hospital stay ([20 days),
were slightly more frequent in Group I (21%) than in
Group II (11%) (p = 0.3). The most frequent complication
was anastomotic failure which occurred in 4 of 27 patients
with coloanal anastomosis who received preoperative
radiation and in 2 of 22 who had primary surgery (Table 3).
Acute grade III toxicity requiring temporary suspension
of radiotherapy appeared in 4 of the 13 patients who
received postoperative chemoradiation. In 8 of 12 (66%)
Table 1 Distribution of clinical and demographic characteristics according to treatment group of 80 patients with rectal cancers classified
primarily with ERUS as T3NxM0
Preoperative chemoradiation
(Group I)
Surgery ± postop
chemoradiation (Group II)
p valuea
(n = 47) (n = 33)
Age at diagnosis (years) (mean ± SD) 63.1 ± 9.4 64.6 ± 12.7 0.6
Gender
Male 28 19
Female 19 14 0.8
Distance of distal margin of tumor from
anal verge at diagnosis (cm) (mean ± SD)
7.1 ± -3.4 7.4 ± -3.0 0.5
Coloanal anastomosesb 27 [4] 21 [3] 0.5
Abdominoperineal excisions 20 (42%) 12 (36%)
Local recurrences 2 (4%) 3 (9%) 0.3
Distant metastases 14 (30%) 8 (24%) 0.5
Alive 33 (70%) 24 (72%)
Dead 14 (30%) 9 (28%) 0.5
a Fisher’s exact test
b Number in square brackets is the number of excisions of the upper internal sphincter
Table 2 Distribution of postoperative pathologic characteristics
according to treatment group of 80 patients with rectal cancers clas-
sified primarily with ERUS as T3NxM0
Preoperative chemoradiation Primary surgery
N (%) N (%)
TNM (pathological)
T0 12 (25) 0
T1 0 0
T2 8 (17) 0
T3 27 (57) 33 (100)
Node? 12 (25) 11 (33)
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patients of Group I and in 8 of 11 of Group II scheduled for
four postoperative extra cycles of chemotherapy, the
treatment was stopped if the patient refused or there was
appearance of grade IV hematologic toxicity.
Local recurrences and survival
Isolated local recurrences were registered in 2 of the 47
Group I patients 3 and 6 years respectively after the
operation; both had clear section margins at operation. In 3
(p = 0.3) of the 33 Group II patients, recurrences (one
isolated and two concomitant to metastatic relapse) had
appeared respectively 6, 9, and 36 months after surgery.
Among the patients who had immediate surgery, two
recurrences were registered out of a total of 22 T3N0
tumors and one out of 11 T3N1 tumors. Recurrence
occurred in one of the three patients with invasion of
section margins.
Of the 80 patients followed for a mean of 92 months, 57
(71%) were still alive at the time of the evaluation. Met-
astatic disease as first relapse was observed in 14 of Group
I and in 8 of Group II patients. Cumulative tumor relapses
(metastatic and/or local) were therefore observed in 34 and
33% of patients of Group I and Group II, respectively
(Table 1). Group I and Group II patients had a 5-year
survival probability of 0.79 (95% CI = 0.49–0.92) and
0.82 (95% CI = 0.70–1.00), respectively (log-rank test,
p = 0.6) (Fig. 1).
In multivariate analysis, adjusting for sex and age as
continuous, Group I had a hazard ratio (HR) for death of
1.4 (95% CI = 0.5–4.1) when compared with Group II.
Disease-free survival was also comparable (HR = 1.1,
95% CI = 0.3–4.4).
No differences in local recurrence, metastatic disease,
disease-free survival, and overall survival were registered
among subgroups of patients who had a complete patho-
logic response, those who were ‘‘downstaged,’’ and those
who were T3N0 after preoperative CT/RT. As expected,
patients with pathologic N? tumors had a significantly
higher incidence of metastatic disease and worse survival
than patients with N- cancers in both Group I and Group
II. However, it must be noted that 11 Group I patients with
positive nodes at surgery died of metastatic disease within
9–48 months. Only six patients in Group II with positive
lymph nodes died of metastatic disease so far (p = 0.04).
Discussion
The aim of this study was to evaluate the effects of a
neoadjuvant treatment with preoperative chemoradiation
versus a selective postoperative approach in patients with
clinically operable low rectal cancers preoperatively staged
as T3. Despite the potential biases due to the small number
of treated patients enrolled in a single center, the lack of
formal randomization, and the self-selection for one of the
two treatment groups, the results of this experience offer
some points of reflection.
The patients evaluated had homogeneous characteristics
and were staged by the same dedicated radiologist who
performed the ERUS. The rate of complete pathologic
response, ‘‘downstaging,’’ or lymphatic invasion following
preoperative chemoradiation was, in Group I patients,
comparable to those reported in the literature [18–20], as
was the rate of positive nodes in the immediate surgery
group [10, 16]. Long-term relapse rate (local and meta-
static) and survival were equivalent in the two groups. We
did not observe a significant increase in the rate of
sphincter-preserving operations after preoperative chemo-
radiation (Table 1). Toxicity from chemoradiation occurred
in 25% of the patients who had preoperative treatment and
in 30% of patients who had postoperative chemoradiation.
Table 3 Major postoperative complications observed in 12 patients
by treatment group
N Complication
Preoperative chemoradiation
2 Intestinal obstructiona
2 Anastomotic failure with pelvic abscess
1 Anastomotic leakage evidenced after loop ileostomy closurea
1 J pouch necrosisa
2 Infection of perineal wound
Primary surgery
2 Anastomotic leakage
1 Pancreatic fistula
1 Prolonged bladder dysfunction
a Reoperation
Overall survival rate
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Fig. 1 Overall survival rate of Groups I and II
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However, the latter represented only the 39% of operated
subjects.
Results of trials on neoadjuvant treatments carried out in
the TME era [10, 21] demonstrated that the main relevant
oncologic effect of this approach is a significant reduction
of local recurrence rate. This reduction, however, is not
always accompanied by a decrease in the number of
metastases and, more important, by an increase in survival
or disease-free survival when compared with surgery alone
or postoperative chemoradiation. This is difficult to explain
if we think that, as reported in a classic study on the natural
history of the operated rectal cancer [22], 25% of patients
with recurrent disease will die from the effects of local
recurrence alone. Some authors [21] explain this apparent
incongruity of the results as being a result of the small
number of local recurrences registered in both arms of their
trial (5.6 vs. 10.9%); indeed in another study [10], the
difference in the number of local recurrences was not so
small (6 vs. 13%), and the survival curves at 5 years were
very similar. Other explanations seem to be warranted.
In our experience 20% of patients who underwent neo-
adjuvant treatment had positive lymph nodes at surgery. As
already reported by others [20, 23, 24], the persistence of
positive lymph nodes after chemoradiation is tied to a high
rate of metastatic failure and subsequent death. In fact, the
outcome of our node-positive (N?) patients after chemo-
radiation was significantly worse than that of patients with
positive nodes in the surgery alone group; remarkably,
when it occurred, metastatic disease appeared earlier and
with a more aggressive behavior in N? patients post-che-
moradiation than in N? patients post-surgery alone. In one
trial [25], the outcome of N? patients after a short course
of preoperative radiotherapy was better than that of per-
sistent N? patients after preoperative chemoradiation. In
the German experience [10], where we must presume a
similar distribution of the worst cancers in the two arms of
the trial, mortality from cancer in patients who had a
relapse was higher in those subjects who had been sub-
jected to the neoadjuvant approach. These data suggest that
preoperative chemoradiation could act as a selection tool
for the worst cancers, but conversely it could also have a
detrimental effect by negatively influencing survival.
In conclusion, from our experience and from an analysis
of the data from the literature, it appears that there is no
clear-cut evidence of a real benefit of preoperative che-
moradiation for the ultimate cure (overall and disease-free
survival) of T3 rectal tumors. Until reliable biological
markers of sensitivity to chemoradiation [26] are devel-
oped and their role as prognostic tools established, in an era
where TME for rectal cancer has obtained wide applica-
tion, the extensive adoption of preoperative chemoradiation
in patients with operable cancer should be critically re-
examined in a randomized trial similar to the MRC CR07
and NCIC-CTG C016 trial [16]. At the moment, the
selective radiochemo postoperative approach maintains its
merit since it reduces the number of subjects who will
experience the morbidity reported by the German trial with
the extensive postoperative approach and the number of
patients with long-term anorectal dysfunction [11]. Pre-
operative chemoradiation should be reserved for use in
very low T3/T4 cancers in patients who refuse a terminal
abdominal stoma or in T3 cancers with deep infiltration of
the mesorectum seen at preoperative MRI, where the
achievement of a satisfactory lateral margin with a standard
TME could be uncertain.
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